Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

AbbVie sees Cerevel’s antipsychotic as ‘best-in-class’ driver of $8.7B deal

Again investing outside immunology, pharma sees differentiation in potential competitor with Karuna’s registrational schizophrenia therapy

December 7, 2023 9:12 PM UTC

AbbVie believes antipsychotic therapy emraclidine can be a viable competitor with Karuna’s registrational asset for schizophrenia, making the M4 agonist the most substantial value component in its $8.7 billion acquisition of Cerevel.

In a presentation early Thursday, AbbVie Inc. (NYSE:ABBV) management described emraclidine as a potential best-in-class asset and a multi-billion-dollar peak sales opportunity. President and COO Robert Michael called it the “most promising” asset in the pipeline of Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE), driving the takeout announced late Wednesday...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article